COST EFFECTIVENESS OF DIFFERENT TARGETED TREATMENT SEQUENCES FOR HER2-POSITIVE METASTATIC BREAST CANCER

被引：0
|
作者：
Diaby, V [1 ]
Adunlin, G. [2 ]
Ali, A. [1 ]
Zeichner, S. [3 ]
Lopes, G. [4 ]
Kohn, C. G. [5 ]
Montero, A. J. [6 ]
机构：
[1] Florida A&M Univ, Tallahassee, FL 32307 USA
[2] Virginia Commonwealth Univ, Richmond, VA USA
[3] Emory Univ, Atlanta, GA 30322 USA
[4] Hosp Coracao & Oncoclin Brasil Grp, Sao Paulo, Brazil
[5] Univ St Joseph, Hartford Hosp, Evidence Based Practice Ctr, Hartford, CT USA
[6] Cleveland Clin, Cleveland, OH 44106 USA
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 03期
关键词：
D O I：
10.1016/j.jval.2016.03.1592
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN93
引用
收藏
页码：A150 / A150
页数：1
相关论文
共 50 条
  • [1] Treatment of HER2-Positive Metastatic Breast Cancer
    van Ramshorst, Mette S.
    Sonke, Gabe S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (20): : 1964 - 1964
  • [2] Recent advances in targeted therapies in the treatment of HER2-positive metastatic breast cancer
    Ismaili, Nabil
    Belbaraka, Rhizlane
    Elomrani, Abdelhamid
    Khouchani, Mouna
    Tahri, Ali
    PRESSE MEDICALE, 2013, 42 (11): : 1461 - 1468
  • [3] Trastuzumab (Herceptin®) for treatment of HER2-positive metastatic breast cancer:: a cost-effectiveness analysis.
    Hornberger, J
    Foutel, V
    Kerrigan, M
    BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 : S136 - S136
  • [4] Exploring Targeted Therapy for HER2-Positive Metastatic Breast Cancer
    Terrie, Yvette C.
    US PHARMACIST, 2022, 47 (10) : 34 - 39
  • [5] Cost-Effectiveness Analysis Of Pertuzumab For Metastatic Her2-Positive Breast Cancer In Japan
    Tange, C.
    Kunisawa, S.
    Maeda, S.
    Shimozuma, K.
    VALUE IN HEALTH, 2015, 18 (07) : A456 - A457
  • [6] Updates in Treatment of HER2-positive Metastatic Breast Cancer
    Alzira R. M. Avelino
    Soumya Pulipati
    Kevin Jamouss
    Prarthna V. Bhardwaj
    Current Treatment Options in Oncology, 2024, 25 (12) : 1471 - 1481
  • [7] The changing treatment of metastatic her2-positive breast cancer
    Mitsogianni, Maria
    Trontzas, Ioannis P.
    Gomatou, Georgia
    Ioannou, Stephanie
    Syrigos, Nikolaos K.
    Kotteas, Elias A.
    ONCOLOGY LETTERS, 2021, 21 (04)
  • [8] Optimizing treatment of HER2-positive metastatic breast cancer
    Jones, AL
    Leyland-Jones, B
    SEMINARS IN ONCOLOGY, 2004, 31 (05) : 29 - 34
  • [9] Margetuximab for the treatment of HER2-positive metastatic breast cancer
    Tarantino, Paolo
    Morganti, Stefania
    Uliano, Jacopo
    Giugliano, Federica
    Crimini, Edoardo
    Curigliano, Giuseppe
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (02) : 127 - 133
  • [10] Profile of Margetuximab: Evidence to Date in the Targeted Treatment of Metastatic HER2-positive Breast Cancer
    Schlam, Ilana
    Nunes, Raquel
    Lynce, Filipa
    ONCOTARGETS AND THERAPY, 2022, 15 : 471 - 478
12345